Samira Mohamad Khalil
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Samira Mohamad Khalil has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Matheus Souza
Department of Internal Medicine, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil
5 shared publications - Lubna Al-Sharif
Department of Biomedical Sciences and Basic Clinical Skills, Faculty of Medicine and Health Sciences An‐Najah National University Nablus Palestine
4 shared publications - Ivanna Diaz
Department of Internal Medicine SUNY Downstate Health Sciences University Brooklyn New York USA
3 shared publications - Alessandro Mantovani
Metabolic Diseases Research Unit IRCCS Sacro Cuore‐Don Calabria Hospital Negrar di Valpolicella Italy
1 shared publication - Chris Elizabeth Philip
Department of Obstetrics and Gynecology, Indiana University School of Medicine, Indianapolis, Indiana, USA
1 shared publication - Cristiane Alves Villela Nogueira
Department of Internal Medicine Federal University of Rio de Janeiro Rio de Janeiro Brazil
1 shared publication
Latest Publications
- 23 August 2025
- Published by Elsevier in Journal of Clinical and Experimental Hepatology
- Vol. 15 (6) , 103173
Placebo Effect on Changes in Magnetic Resonance-based Endpoints in Patients With MASH: Systematic Review and Meta-analysis
- 23 August 2025
- Published by Elsevier in Journal of Clinical and Experimental Hepatology
- Vol. 15 (6) , 103173
Placebo Effect on Changes in Magnetic Resonance-based Endpoints in Patients With MASH: Systematic Review and Meta-analysis
- 16 July 2025
- Published by Wiley in Journal of Pediatric Gastroenterology and Nutrition
- Vol. 81 (3) , 663-673
Meta‐analysis: Histological severity of biopsy‐proven metabolic dysfunction‐associated steatotic liver disease in pediatric patients
The burden of metabolic dysfunction‐associated steatotic liver disease (MASLD) is increasing in children and adolescents. However, the severity of disease at diagnosis by liver biopsy remains uncertain and has not been systematically evaluated. We conducted a systematic review and meta‐analysis to determine the prevalence of metabolic dysfunction‐associated steatohepatitis (MASH), significant and advanced fibrosis in this population. PubMed and Embase databases were systematically searched (from inception to September 17, 2024) for studies reporting liver histology in pediatric patients (≤21 years) with biopsy‐proven MASLD. Meta‐analysis of proportions was performed using a generalized linear mixed model with Clopper‐Pearson intervals to obtain pooled prevalence estimates. Of 4761 records identified, we included 35 studies with 5898 pediatric patients with biopsy‐proven MASLD (33.4% girls; mean age 12.6 years). The pooled prevalences of MASH, significant fibrosis (defined as ≥F2) and advanced fibrosis (defined as ≥F3) based on histology were 59.95% ( n = 18 studies, 95% confidence interval [CI]: 46.89–71.73, I ² = 97%), 30.53% ( n = 26 studies, 95% CI: 22.32–40.20, I ² = 94%), and 11.77% ( n = 28 studies, 95% CI: 8.10–16.80, I ² = 89%), respectively. Subgroup analyses showed higher prevalence of advanced fibrosis in studies with <100 patients compared to larger studies. Meta‐regressions did not show an influence of age, sex, and body mass index on the prevalences. Sensitivity analyses did not modify these results. Pediatric patients have considerable severity of MASLD at diagnosis by liver biopsy. Developing effective screening and risk stratification strategies for this group is urgently needed.
- 16 July 2025
- Published by Wiley in Journal of Pediatric Gastroenterology and Nutrition
- Vol. 81 (3) , 663-673
Meta‐analysis: Histological severity of biopsy‐proven metabolic dysfunction‐associated steatotic liver disease in pediatric patients
The burden of metabolic dysfunction‐associated steatotic liver disease (MASLD) is increasing in children and adolescents. However, the severity of disease at diagnosis by liver biopsy remains uncertain and has not been systematically evaluated. We conducted a systematic review and meta‐analysis to determine the prevalence of metabolic dysfunction‐associated steatohepatitis (MASH), significant and advanced fibrosis in this population. PubMed and Embase databases were systematically searched (from inception to September 17, 2024) for studies reporting liver histology in pediatric patients (≤21 years) with biopsy‐proven MASLD. Meta‐analysis of proportions was performed using a generalized linear mixed model with Clopper‐Pearson intervals to obtain pooled prevalence estimates. Of 4761 records identified, we included 35 studies with 5898 pediatric patients with biopsy‐proven MASLD (33.4% girls; mean age 12.6 years). The pooled prevalences of MASH, significant fibrosis (defined as ≥F2) and advanced fibrosis (defined as ≥F3) based on histology were 59.95% ( n = 18 studies, 95% confidence interval [CI]: 46.89–71.73, I ² = 97%), 30.53% ( n = 26 studies, 95% CI: 22.32–40.20, I ² = 94%), and 11.77% ( n = 28 studies, 95% CI: 8.10–16.80, I ² = 89%), respectively. Subgroup analyses showed higher prevalence of advanced fibrosis in studies with <100 patients compared to larger studies. Meta‐regressions did not show an influence of age, sex, and body mass index on the prevalences. Sensitivity analyses did not modify these results. Pediatric patients have considerable severity of MASLD at diagnosis by liver biopsy. Developing effective screening and risk stratification strategies for this group is urgently needed.
- 31 May 2025
- Published by Elsevier in Journal of Clinical and Experimental Hepatology
- Vol. 15 (6) , 102603
Prevalence of Binge Eating Disorder in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Meta-analysis
- 31 May 2025
- Published by Elsevier in Journal of Clinical and Experimental Hepatology
- Vol. 15 (6) , 102603
Prevalence of Binge Eating Disorder in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Meta-analysis
- 5 May 2025
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 120 (11) , 2709-2713
Enrollment in Metabolic Dysfunction-Associated Steatohepatitis Clinical Trials: A Pooled Analysis of Screen Failure Rates
INTRODUCTION: Screen failure is a major challenge in the enrollment of metabolic dysfunction-associated steatohepatitis (MASH) randomized controlled trials (RCTs), but its impact has not been systematically assessed. METHODS: We searched PubMed and the Cochrane Library databases for phase ≥2 RCTs of MASH pharmacotherapies in adults using histological inclusion criteria. Screen failure rates (SFRs) were pooled using a generalized linear mixed model. RESULTS: Of 67 included RCTs, 58 reported enrollment data. The pooled SFR was 56.28% (95% confidence interval 50.14–62.23) in 44,949 individuals. The most common reason for screen failure was ineligibility. SFR was higher in more recent trials, globally conducted trials, and trials funded by pharmaceutical companies. Meta-regressions showed an increase in SFR over time and with more trial sites. DISCUSSION: Evidence-based strategies to reduce the high SFR in MASH clinical trials are urgently needed.
- 5 May 2025
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 120 (11) , 2709-2713
Enrollment in Metabolic Dysfunction-Associated Steatohepatitis Clinical Trials: A Pooled Analysis of Screen Failure Rates
INTRODUCTION: Screen failure is a major challenge in the enrollment of metabolic dysfunction-associated steatohepatitis (MASH) randomized controlled trials (RCTs), but its impact has not been systematically assessed. METHODS: We searched PubMed and the Cochrane Library databases for phase ≥2 RCTs of MASH pharmacotherapies in adults using histological inclusion criteria. Screen failure rates (SFRs) were pooled using a generalized linear mixed model. RESULTS: Of 67 included RCTs, 58 reported enrollment data. The pooled SFR was 56.28% (95% confidence interval 50.14–62.23) in 44,949 individuals. The most common reason for screen failure was ineligibility. SFR was higher in more recent trials, globally conducted trials, and trials funded by pharmaceutical companies. Meta-regressions showed an increase in SFR over time and with more trial sites. DISCUSSION: Evidence-based strategies to reduce the high SFR in MASH clinical trials are urgently needed.
- 3 March 2025
- Published by Wiley in Liver International
- Vol. 45 (4) , e70029
Representation of Sex, Race and Ethnicity in MASH Randomised Controlled Trials: A Systematic Review and Meta‐Analysis
Background and Aims: Randomised controlled trials (RCTs) have historically underrepresented female, racial and ethnic minorities across various fields. This systematic review and meta‐analysis aims to examine the global distribution, reporting and participation of diverse groups based on sex, race and ethnicity in trials focused on metabolic dysfunction‐associated steatohepatitis (MASH). Methods: PubMed and Cochrane Library databases were systematically searched for MASH RCTs (through December 13, 2024) that included any pharmacotherapy as an intervention arm. RCTs were qualitatively reviewed to assess their global distribution and reporting of populations. A meta‐analysis of proportions was performed using a generalised linear mixed model. Results: One hudred and nine studies were identified, reporting data from 112 RCTs and 19 516 MASH participants. Of the 49 countries that conducted trials, 34 were high‐income countries (69.4%). Sex, race and ethnicity were reported in 111 (99.1%), 69 (61.6%) and 56 (50.0%) of the 112 RCTs, respectively, with reporting improving in recent years. We found no reporting of sexual and gender minorities. The pooled proportions of female, White, Asian, Black and Hispanic/Latino groups were 54.23% (95% confidence interval [CI]: 51.31–57.12), 87.63% (95% CI: 85.37–89.58), 4.95% (95% CI: 3.42–7.10), 2.27% (95% CI: 1.89–2.71) and 31.42% (95% CI: 26.61–36.66), respectively. Meta‐regressions showed a trend toward more female, White and Hispanic/Latino participants in RCTs over time. Conclusions: Although female and Hispanic/Latino representation has increased over time, racial minorities are underrepresented in MASH trials. These data provide an overview of participant representation in MASH trials and call for collaborative efforts among researchers, sponsors, regulators and other relevant stakeholders to improve diversity in these trials.
- 3 March 2025
- Published by Wiley in Liver International
- Vol. 45 (4) , e70029
Representation of Sex, Race and Ethnicity in MASH Randomised Controlled Trials: A Systematic Review and Meta‐Analysis
Background and Aims: Randomised controlled trials (RCTs) have historically underrepresented female, racial and ethnic minorities across various fields. This systematic review and meta‐analysis aims to examine the global distribution, reporting and participation of diverse groups based on sex, race and ethnicity in trials focused on metabolic dysfunction‐associated steatohepatitis (MASH). Methods: PubMed and Cochrane Library databases were systematically searched for MASH RCTs (through December 13, 2024) that included any pharmacotherapy as an intervention arm. RCTs were qualitatively reviewed to assess their global distribution and reporting of populations. A meta‐analysis of proportions was performed using a generalised linear mixed model. Results: One hudred and nine studies were identified, reporting data from 112 RCTs and 19 516 MASH participants. Of the 49 countries that conducted trials, 34 were high‐income countries (69.4%). Sex, race and ethnicity were reported in 111 (99.1%), 69 (61.6%) and 56 (50.0%) of the 112 RCTs, respectively, with reporting improving in recent years. We found no reporting of sexual and gender minorities. The pooled proportions of female, White, Asian, Black and Hispanic/Latino groups were 54.23% (95% confidence interval [CI]: 51.31–57.12), 87.63% (95% CI: 85.37–89.58), 4.95% (95% CI: 3.42–7.10), 2.27% (95% CI: 1.89–2.71) and 31.42% (95% CI: 26.61–36.66), respectively. Meta‐regressions showed a trend toward more female, White and Hispanic/Latino participants in RCTs over time. Conclusions: Although female and Hispanic/Latino representation has increased over time, racial minorities are underrepresented in MASH trials. These data provide an overview of participant representation in MASH trials and call for collaborative efforts among researchers, sponsors, regulators and other relevant stakeholders to improve diversity in these trials.
- 19 September 2023
- Published by Wiley in International Journal of Gynecology & Obstetrics
- Vol. 165 (1) , 107-116
Single‐dose oral azithromycin prophylaxis in planned vaginal delivery for sepsis prevention: A systematic review and meta‐analysis of randomized controlled trials
Introduction: The use of oral azithromycin (AZI) as a preventive measure against postpartum infections of planned vaginal births has garnered a lot of interest in recent years and has been the subject of many randomized controlled trials (RCTs). However, the results from these trials have not been consistent. Therefore, we aim to perform a systematic review and meta‐analysis to determine whether the use of a single‐dose of oral AZI is clinically significant.Methods: We systematically searched PubMed, Embase, and Cochrane Central for RCTs from May to June 2023, comparing a single dose of oral AZI with placebo in patients undergoing planned vaginal delivery at a minimum of 28 weeks of gestational age. The main outcomes were puerperal and neonatal sepsis. Statistical analyses were performed using Review Manager 5.4.1 (Cochrane Collaboration). Heterogeneity was assessed with I2 statistics.Results: Four RCTs were included (mothers, n = 42 235; newborns n = 42 492). Approximately 49.8% of mothers received a single dose of oral AZI for sepsis prophylaxis. Compared with placebo, AZI significantly reduced the incidence of puerperal sepsis (risk ratio [RR], 0.65 [95% confidence interval (CI), 0.55–0.77]; P < 0.001), mastitis or breast abscess (RR, 0.58 [95% CI, 0.42–0.79]; P < 0.001), endometritis (RR, 0.65 [95% CI, 0.54–0.77]; P < 0.001), wound infection (RR, 0.81 [95% CI, 0.69–0.96]; P = 0.013), infection rate (RR, 0.62 [95% CI, 0.51–0.76]; P < 0.001), and fever (RR, 0.50 [95% CI, 0.28–0.89]; P = 0.018) in mothers. No statistically significant differences were identified between groups regarding maternal all‐cause mortality and the use of prescribed postpartum antibiotics. Similarly, no statistical differences were noted in the neonatal group regarding sepsis, infection rate, and all‐cause mortality.Conclusion: AZI appears to be an effective preventive measure against many postpartum infections in mothers but a substantial impact on neonatal outcomes has not yet been conclusively observed.
- 19 September 2023
- Published by Wiley in International Journal of Gynecology & Obstetrics
- Vol. 165 (1) , 107-116
Single‐dose oral azithromycin prophylaxis in planned vaginal delivery for sepsis prevention: A systematic review and meta‐analysis of randomized controlled trials
Introduction: The use of oral azithromycin (AZI) as a preventive measure against postpartum infections of planned vaginal births has garnered a lot of interest in recent years and has been the subject of many randomized controlled trials (RCTs). However, the results from these trials have not been consistent. Therefore, we aim to perform a systematic review and meta‐analysis to determine whether the use of a single‐dose of oral AZI is clinically significant.Methods: We systematically searched PubMed, Embase, and Cochrane Central for RCTs from May to June 2023, comparing a single dose of oral AZI with placebo in patients undergoing planned vaginal delivery at a minimum of 28 weeks of gestational age. The main outcomes were puerperal and neonatal sepsis. Statistical analyses were performed using Review Manager 5.4.1 (Cochrane Collaboration). Heterogeneity was assessed with I2 statistics.Results: Four RCTs were included (mothers, n = 42 235; newborns n = 42 492). Approximately 49.8% of mothers received a single dose of oral AZI for sepsis prophylaxis. Compared with placebo, AZI significantly reduced the incidence of puerperal sepsis (risk ratio [RR], 0.65 [95% confidence interval (CI), 0.55–0.77]; P < 0.001), mastitis or breast abscess (RR, 0.58 [95% CI, 0.42–0.79]; P < 0.001), endometritis (RR, 0.65 [95% CI, 0.54–0.77]; P < 0.001), wound infection (RR, 0.81 [95% CI, 0.69–0.96]; P = 0.013), infection rate (RR, 0.62 [95% CI, 0.51–0.76]; P < 0.001), and fever (RR, 0.50 [95% CI, 0.28–0.89]; P = 0.018) in mothers. No statistically significant differences were identified between groups regarding maternal all‐cause mortality and the use of prescribed postpartum antibiotics. Similarly, no statistical differences were noted in the neonatal group regarding sepsis, infection rate, and all‐cause mortality.Conclusion: AZI appears to be an effective preventive measure against many postpartum infections in mothers but a substantial impact on neonatal outcomes has not yet been conclusively observed.